Patents by Inventor Richard M. Condie

Richard M. Condie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 4296027
    Abstract: Isolated and purified natural, unaltered, undenatured immune gamma globulin (IgG) for intravenous administration prepared from animal blood plasma, especially human. The products are characterized by high yield and high purity. They are unfragmented and unaggregated, i.e., natural preparation.
    Type: Grant
    Filed: January 22, 1979
    Date of Patent: October 20, 1981
    Assignee: The Regents of the University of Minnesota
    Inventor: Richard M. Condie
  • Patent number: 4136094
    Abstract: A method of isolating and purifying natural, unaltered, undenatured immune gamma globulin (IgG) for intravenous administration and albumin from animal blood plasma, especially human, and the resulting products. The method involves the initial stabilization of plasma by treatment with silica, or the use of previously stabilized plasma. IgG and albumin are isolated from the stabilized plasma by chromatographic reaction with sterile ion exchange resin and eluted by adjustment of pH and ionic strength. The products are concentrated, purified further and packaged. They are characterized by high yield and high purity. They are unfragmented and unaggregated, i.e., natural preparation.
    Type: Grant
    Filed: August 31, 1977
    Date of Patent: January 23, 1979
    Assignee: The Regents of the University of Minnesota
    Inventor: Richard M. Condie
  • Patent number: 3998946
    Abstract: A method of treating blood plasma or fractionated plasma products with fumed colloidal silica to remove fibrinogen without polymerization to fibrin, to remove the plasminogen-plasmin proteolytic enzyme system, to remove cholesterol and lipoproteins and reduce triglycerides, while maintaining plasma coagulation factor II at pretreatment levels and leaving immunoglobulins and other protein constitutents unaffected, and the resulting product. Plasma products treated with fumed silica may be subjected to long-term storage for a year or more without loss of its biologically active support properties, thereby circumventing the problem of hepatitis. The treated plasma products, either fresh or after long-term storage, may be used as a perfusion support media for organ perfusion, for treatment of hemmorrhagic shock and similar purposes for which untreated plasma and fractionated plasma products are customarily used, with equal or superior effectiveness.
    Type: Grant
    Filed: April 23, 1975
    Date of Patent: December 21, 1976
    Assignee: The Regents of the University of Minnesota
    Inventors: Richard M. Condie, Luis H. Toledo-Pereyra